• 
  Home
• 
  News
• P&T Journal
  Complete Contents
• P&T
  TV
• Product
  Profilers
• 
  Resources 
  • Pharmacy Policies/Procedures
  • Cost Calculators
  • Links

• All 
  • Abilify Maintena™(aripiprazole)
    for extended-release injectable suspension
    Please click for FULL PRESCRIBING INFORMATION including Boxed WARNING
  • BRILINTA®
    (ticagrelor) tablets
  • Eliquis®
    (apixaban) tablets
  • FORTESTA®
    (testosterone) Gel
  • INVOKANA™
    (canagliflozin)
  • JAKAFI®
    (ruxolitinib) tablets
  • KOMBIGLYZE™ XR
    (saxagliptin and metformin HCl extended-release) tablets
  • LINZESS™
    (linaclotide) capsules
    145 mcg • 290 mcg
  • Onglyza®
    (saxagliptin)
  • PREVNAR®
    (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])
  • Quillivant XR™
    (methylphenidate HCl)
    for extended-release oral suspension, CII
    Please click for FULL PRESCRIBING INFORMATION, including Boxed WARNING
  • RAVICTI™
    (glycerol phenylbutyrate)
  • SYMBICORT®
    (budesonide/formoterol
    fumarate dihydrate)
  • Teflaro®
    (ceftaroline fosamil) for injection 600 mg • 400 mg
• New 
  • Abilify Maintena™(aripiprazole)
    for extended-release injectable suspension
    Please click for FULL PRESCRIBING INFORMATION including Boxed WARNING
  • Eliquis®
    (apixaban) tablets
  • FORTESTA®
    (testosterone) Gel
  • INVOKANA™
    (canagliflozin)
  • JAKAFI®
    (ruxolitinib) tablets
  • LINZESS™
    (linaclotide) capsules
    145 mcg • 290 mcg
  • Quillivant XR™
    (methylphenidate HCl)
    for extended-release oral suspension, CII
    Please click for FULL PRESCRIBING INFORMATION, including Boxed WARNING
  • RAVICTI™
    (glycerol phenylbutyrate)
  • SYMBICORT®
    (budesonide/formoterol
    fumarate dihydrate)
  • Teflaro®
    (ceftaroline fosamil) for injection 600 mg • 400 mg
• Updated 
  • BRILINTA®
    (ticagrelor) tablets
  • Eliquis®
    (apixaban) tablets
  • KOMBIGLYZE™ XR
    (saxagliptin and metformin HCl extended-release) tablets
  • Onglyza®
    (saxagliptin)
  • PREVNAR®
    (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

News Categories

• Clinical Trials
• Research News
• Industry Trends
• Agency Actions
• Drug Safety Issues
• Approvals, Launches, & New Indications
• Health Care Reform
• Guidelines

Correction

An article in the September issue of P&T, page 502, incorrectly stated that the FDA considers Vascepa to be a new chemical entity (NCE). In fact, the FDA has not yet decided whether to grant the drug new chemical entity marketing exclusivity. P&T regrets the error.

FDA Approves New Ultrasound Treatment for Pain From Bone Metastases  

 

New Radiation Technique Linked to More Complications in Breast Cancer Patients